Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Service Year-Dependent Disruption of Reproductive Hormones and Altered DNA Methylation in Male Firefighters.

Journal of occupational and environmental medicine·2026
Same author

Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content.

Journal of lipid research·2025
Same author

Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns.

Metabolomics : Official journal of the Metabolomic Society·2025
Same author

Stationary phase effects in hydrophilic interaction liquid chromatographic separation of oligonucleotides.

The Analyst·2024
Same author

Endocrine-Disrupting Chemicals: A Looming Threat to Current and Future Generations.

International journal of molecular sciences·2024
Same author

Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells.

Epigenetics communications·2024

Related Experiment Video

Updated: Mar 7, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K

Ca2+ Selective Host Rotaxane Is Highly Toxic Against Prostate Cancer Cells.

David B Smithrud1, Lucas Powers1, Jennifer Lunn1

  • 1Contribution from the Department of Chemistry, University of Cincinnati , Cincinnati, Ohio 45221, United States.

ACS Medicinal Chemistry Letters
|February 16, 2017
PubMed
Summary

New rotaxanes show promise for treating prostate cancer. A novel crown ether rotaxane (CEHR2) selectively binds calcium ions (Ca2+), enhancing toxicity against cancer cells, offering a potential new therapy for advanced prostate cancer.

Keywords:
Prostate cancercalciumcrown ethersrotaxanes

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Area of Science:

  • Supramolecular Chemistry
  • Oncology
  • Materials Science

Background:

  • Androgen-resistant prostate cancer requires novel therapeutic strategies.
  • Prostate cancer often metastasizes to bone, a calcium-rich environment.
  • Existing ionophores for metal cation delivery are too toxic for clinical use.

Purpose of the Study:

  • To design and synthesize a novel rotaxane capable of selective calcium ion (Ca2+) binding.
  • To evaluate the efficacy of the synthesized rotaxane in delivering Ca2+ into cancer cells.
  • To assess the therapeutic potential of Ca2+-binding rotaxanes against prostate cancer cell lines.

Main Methods:

  • Synthesis of a new rotaxane, CEHR2, featuring a benzyl 15-crown-5 ether for Ca2+ binding.
  • Investigated cation transfer selectivity of CEHR2 using aqueous solutions and chloroform.
  • Assessed the cytotoxicity of CEHR2 and a control rotaxane (CEHR1) against human prostate cancer cell lines (PC-3, 22Rv1, C4-2).

Main Results:

  • CEHR2 demonstrated efficient transfer of Ca2+ over alkali metal cations and Mg2+.
  • CEHR2 exhibited superior Ca2+ transfer capabilities compared to CEHR1 (containing an 18-crown-6 ether).
  • CEHR2 showed significantly enhanced toxicity against PC-3, 22Rv1, and C4-2 prostate cancer cells compared to CEHR1.

Conclusions:

  • Crown ether rotaxanes can be rationally designed for selective metal cation binding.
  • Targeted Ca2+ association via rotaxanes can lead to enhanced cytotoxicity.
  • This approach offers a promising strategy for developing new therapies for androgen-resistant prostate cancer.